The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
|Articles|August 3, 2022
Pfizer-BioNTech Begin Study Looking at Enhanced COVID-19 Vaccine
Author(s)John Parkinson
The modified spike protein in this next-generation bivalent candidate is part of the companies' strategy to try and provide vaccines with longer and more durable protection against the virus.
Advertisement
The 2 companies recently announced they had begun a phase 2 trial looking at this new candidate, BNT162b5, at a 30 µg dose level in a randomized, active-controlled, observer-blind study.
Pfizer-BioNTech are calling the candidate a next-generation bivalent COVID-19 vaccine that has RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
The enhanced spike protein encoded from the mRNAs in BNT162b5 has been modified with the aim of increasing the magnitude and breadth of the immune response that could better protect against COVID-19.
The study will be conducted in the United States and looks to enroll approximately 200 participants between 18 and 55 years of age and who have received 1 booster dose of a US-authorized COVID-19 vaccine at least 90 days prior to their first study visit.
This is part of the companies’ strategy to look to generate longer-lasting immune responses against SARS-CoV-2 infections.
Advertisement
Related to this article
An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.
Labcorp data presented at IDWeek 2026 show measles PCR testing nearly quadrupled and positivity rose sharply from April 2025 through March 2026, as clinicians shift toward guideline-recommended molecular testing amid ongoing US outbreaks.
Company announces first AI-designed personalized phage treatment for antibiotic-resistant bacterial infection in human patient.
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
3
Thinking Outside the IV: Implementation of a COpAT Program for Patients With Bone and Joint Infections
4
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
5